Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study

Fusco, Ferdinando; Creta, Massimiliano; Persico, Francesco; Franco, Marco; Mirone, Vincenzo

doi:10.1186/s12894-018-0326-7

Cited by 6 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is hypothesized that the subjects with a moderate-to-high compromised baseline level might have a greater margin of improvement compared with subjects that are less compromised at baseline, however, further studies are needed. 50 Chapple et al provided evidence that silodosin can be used for the treatment of both storage and voiding LUTS associated with BPH. Here the change from baseline in the IPSS total score with silodosin (difference, −2.3, 95% confidence interval [CI], −3.2, −1.4) and tamsulosin (difference, −2.0; 95% CI: −2.9, −1.1) was significantly superior to that with placebo (P < 0.001); number of responders with total IPSS were significantly higher (P < 0.001) with silodosin (66.8%) and tamsulosin (65.4%) than with placebo (50.8%) after 12 weeks of treatment.…”

Section: Methodsmentioning

confidence: 99%

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Jin-dan¹,

Wang²,

Xie³

2022

DDDT

View full text Add to dashboard Cite

Use of α-androgenic receptor blockers remains a mainstay therapeutic approach for the treatment of urological diseases. Silodosin is recommended over other α-blockers for the treatment of lower urinary tract symptoms (LUTS) and benign prostate hyperplasia (BPH), due to its high α 1A uroselectivity. Current research data suggest that silodosin is efficacious in the management of various urological diseases. Thus, we herein review the current evidence of silodosin related to its efficacy and tolerability and appraise the available literature that might ultimately aid in management of various urological conditions at routine clinical practice. Literature reveals that silodosin is beneficial in improving nocturia events related to LUTS/BPH. Silodosin exerts effect on relaxing muscles involved in detrusor obstruction, therefore prolonging the need for patients undergoing invasive surgery. Silodosin treatment, either as a monotherapy or combination, significantly improves International Prostate Symptom Score (IPSS) including both storage and voiding symptoms in patients with BPH/LUTS. Patients on other treatment therapies such as phosphodiesterase 5 inhibitors or other α-blockers are well managed with this drug. Steadily, silodosin has proved beneficial in the treatment of other urological disorders such as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), overactive bladder/acute urinary retention (AUR), premature ejaculation (PE), and prostate cancer post brachytherapy-induced progression. In patients with distal ureteral stones, silodosin treatment is beneficial in decreasing stone expulsion time without affecting stone expulsion rate or analgesic need. Moreover, there were significant improvements in intravaginal ejaculation latency time, quality of life scores, and decrease in PE profile among patients with PE. Silodosin has also demonstrated promising results in increasing the likelihood of successful trial without catheter in patients with AUR and those taking antihypertensive drugs. Reports from Phase II studies have shown promising role of silodosin in the treatment of CP/CPPS as well as facilitating ureteral stone passage. From the robust data in this review, further silodosin treatment strategies in the management of different urological conditions need to be focused on.

show abstract

Section: Methodsmentioning

confidence: 99%

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Jin-dan¹,

Wang²,

Xie³

2022

DDDT

View full text Add to dashboard Cite

show abstract

“…Surgery was delayed due to the urodynamic improvements. 36 Distal ureteral calculi (max 10mm stone size) expulsion time was very short with silodosin and has been discontinued after the expulsion. It is a short, safe, effective and more rational treatment choice than invasive or other medical methods.…”

Section: Silodosin and Stone Expulsion Via Surgical Interventionmentioning

confidence: 99%

The efficacy and safety of silodosin-a review of literature

Faikoglu¹,

Saygisever-Faikoglu²,

Ozcan³

et al. 2021

PPIJ

View full text Add to dashboard Cite

Background: Benign prostatic hyperplasia is a compilation of irritative voiding and obstructive symptoms which are consistent with reduced emptying of urine from and defective storage of urine in the bladder. Medications are a common method of treatment to delay complications and reduce symptoms. Silodosin is a highly selective alpha-1A adrenoceptor blocker that has 162 times more affinity for alpha-1a than alpha 1b, thus resulting in high uroselectivity and decreased side effects. Aim:In this review article our aim was to elucidate the clinical effects, safety and tolerability profile of silodosin in the treatment of benign prostatic hyperplasia.Method: Literatures were retrieved by a PubMed search, using different combinations of pertinent keywords (e.g., silodosin, hypotension, benign prostatic hyperplasia), without any limitations in terms of publication date and language. Papers which assessed the therapeutic efficacy and tolerability of silodosin were selected for inclusion according to their relevance for the topic, as judged by the authors. Overvıew of clinical data:Silodosin is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. It has a rapid onset of effect in men with lower urinary tract symptoms and improvements were seen in voiding and storage symptoms, maximum urinary flow rate and health-related quality of life. The efficacy of silodosin was maintained in several controlled studies and also non-interventional real-world setting. Silodosin was generally well tolerated. Conclusion:Silodosin is the most uroselective α-blocker. Silodosin has been emphasized in the 2021 European Association of Urology Conservative treatment of non-neurogenic male LUTS guidelines and it has been reported that the hypotensive effect of silodosin is comparable with placebo and has favorable safety and tolerability profile. Dosing of silodosin does not need to be adjusted according to age, concurrent medication with antihypertensives and phosphodiesterase type 5 inhibitors.

show abstract

“… 7 An explorative clinical study investigated the effects of silodosin 8 mg once daily on obstruction urodynamic parameters and subjective symptoms in 30 Caucasian patients. 9 All enrolled patients were obstructed (BOOI >40), reporting dissatisfaction with previous drug treatments and complained of severe symptoms for which they were awaiting surgery. The magnitude of BOOI improvement was both statistically and clinically significant, and 53.3% of patients improved their class according to BOOI (obstructed to unobstructed/obstructed to equivocal/equivocal to unobstructed).…”

Section: Pharmacological Uroselectivity Influences Urodynamic Efficacmentioning

confidence: 99%

“…Most interestingly, at the end of the treatment all patients declared that their condition improved enough to spare or delay surgery. 9 …”

Section: Pharmacological Uroselectivity Influences Urodynamic Efficacmentioning

confidence: 99%

Focus on Silodosin: Pros and Cons of Uroselectivity

Califano

Ruvolo

Creta

et al. 2020

RRU

Self Cite

View full text Add to dashboard Cite

Medical management of lower urinary tract symptoms related to benign prostatic obstruction engages healthcare professionals worldwide. Currently, alpha-1 adrenergic antagonists are strongly recommended as first-line therapy for patients with moderate to severe symptoms because of their safety, efficacy and good tolerability. These agents are highly heterogeneous in terms of pharmacological selectivity for the adrenergic receptor subtypes with silodosin being the agent characterized by the highest α 1A /α 1B affinity ratio. This property has been proposed to confer to silodosin advantages in terms of bladder outlet obstruction improvement and lower incidence of cardiovascular side effects at the cost of a higher incidence of ejaculatory dysfunction. These aspects should be carefully taken in consideration when personalizing medical therapy for lower urinary tract symptoms related to benign prostatic obstruction.

show abstract

Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study

Cited by 6 publications

References 20 publications

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

The efficacy and safety of silodosin-a review of literature

Focus on Silodosin: Pros and Cons of Uroselectivity

Contact Info

Product

Resources

About